Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
about
New perspectives in glioblastoma antiangiogenic therapyDevelopment of targeted therapies in treatment of glioblastomaA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesMutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseSpectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.The challenges and the promise of molecular targeted therapy in malignant gliomas.Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.Prioritization schema for immunotherapy clinical trials in glioblastoma.Anti-cancer Therapies in High Grade Gliomas.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.Glioblastoma targeted therapy: updated approaches from recent biological insights.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Reduced PTEN expression and overexpression of miR-17-5p, -19a-3p, -19b-3p, -21-5p, -130b-3p, -221-3p and -222-3p by glioblastoma stem-like cells following irradiation.PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysisA novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastomaMolecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.
P2860
Q26746028-52DC9D1D-0344-4A40-914A-E9D923D362EFQ26778787-DF0133AB-4E5F-4BDC-BBF1-88BF8025DCCDQ26851160-96EEEE93-5CED-4E68-8480-35CE95EA66DFQ26862516-2FFD446C-7869-4AE3-83DE-7113697A54A5Q31162700-1A85FBD7-C1CE-4A76-925F-680CA960BE2CQ35036895-B62711ED-C44A-483F-9D43-5A22D3948C48Q35214534-CD507080-534F-4025-900C-DD9E93A4D84BQ36705913-7092C1E9-87D2-442F-BCCA-62B2E0B099B8Q37078999-B8DD5F49-EBAC-43E1-8054-7EED0D2798FDQ37290626-0AAD000E-BA1A-4C15-B6DA-E2858BBF3ADAQ37471694-7F1F9129-7521-4CBE-BFD5-68316E9289F8Q38272728-654AFE9D-BCE6-4D54-BD62-3723583131D3Q38593312-497122C0-DE2F-42D3-A91F-CBCC0DE32AA1Q38597700-51A73F99-FAB2-4EE3-961D-4F9804FD3622Q38694765-285A2131-FB00-4F07-AF77-2047DC81C98CQ38815443-D0FD7E8C-B6C0-438E-A027-68C2C8C0C585Q39640325-C6BD3EBF-5607-4B5D-AFBB-D40FEA81A2D6Q41841115-2B14B963-9B65-479A-BFE5-07E49CC6B48EQ47130146-B4B9D853-45AB-45FD-B9DB-18780424C016Q50033966-C9790F5D-4E16-4734-B5B8-DC52FE214C81
P2860
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@en
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@nl
type
label
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@en
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@nl
prefLabel
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@en
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab.
@nl
P2093
P50
P921
P356
P1476
Correlation of EGFR, IDH1 and ...... monoclonal antibody cetuximab
@en
P2093
Alex Michotte
Erik Teugels
Jan Sadones
Stephanie Du Four
Sylvia De Brakeleer
P304
P356
10.3892/IJO.2012.1539
P577
2012-06-29T00:00:00Z